vs
PATHWARD FINANCIAL, INC.（CASH）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$276.3M vs $207.3M），PATHWARD FINANCIAL, INC.净利率更高（26.4% vs -62.0%，领先88.4%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 21.0%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CASH vs RARE — 直观对比
营收规模更大
CASH
是对方的1.3倍
$207.3M
净利率更高
CASH
高出88.4%
-62.0%
两年增速更快
RARE
近两年复合增速
21.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $276.3M | $207.3M |
| 净利润 | $72.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 26.4% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $3.35 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHRARE
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | $207.3M | ||
| Q3 25 | $186.7M | $159.9M | ||
| Q2 25 | $195.8M | $166.5M | ||
| Q1 25 | $274.8M | $139.3M | ||
| Q4 24 | $182.6M | $164.6M | ||
| Q3 24 | $179.5M | $139.5M | ||
| Q2 24 | $188.6M | $147.0M |
净利润CASHRARE
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | $-128.6M | ||
| Q3 25 | $38.8M | $-180.4M | ||
| Q2 25 | $42.1M | $-115.0M | ||
| Q1 25 | $75.0M | $-151.1M | ||
| Q4 24 | $30.0M | $-133.2M | ||
| Q3 24 | $33.5M | $-133.5M | ||
| Q2 24 | $44.9M | $-131.6M |
营业利润率CASHRARE
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | -54.7% | ||
| Q3 25 | 25.9% | -106.9% | ||
| Q2 25 | 24.1% | -64.8% | ||
| Q1 25 | 33.2% | -102.6% | ||
| Q4 24 | 19.8% | -74.3% | ||
| Q3 24 | 20.9% | -94.6% | ||
| Q2 24 | 27.1% | -79.1% |
净利率CASHRARE
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | -62.0% | ||
| Q3 25 | 20.8% | -112.8% | ||
| Q2 25 | 21.5% | -69.0% | ||
| Q1 25 | 27.3% | -108.5% | ||
| Q4 24 | 16.4% | -80.9% | ||
| Q3 24 | 18.7% | -95.7% | ||
| Q2 24 | 23.8% | -89.5% |
每股收益（稀释后）CASHRARE
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | $-1.28 | ||
| Q3 25 | $1.69 | $-1.81 | ||
| Q2 25 | $1.81 | $-1.17 | ||
| Q1 25 | $3.14 | $-1.57 | ||
| Q4 24 | $1.23 | $-1.34 | ||
| Q3 24 | $1.34 | $-1.40 | ||
| Q2 24 | $1.78 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.6M | $421.0M |
| 总债务越低越好 | $59.5M | — |
| 股东权益账面价值 | $850.7M | $-80.0M |
| 总资产 | $7.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资CASHRARE
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | $421.0M | ||
| Q3 25 | $120.6M | $202.5M | ||
| Q2 25 | $258.3M | $176.3M | ||
| Q1 25 | $254.2M | $127.1M | ||
| Q4 24 | $597.4M | $174.0M | ||
| Q3 24 | $158.3M | $150.6M | ||
| Q2 24 | $298.9M | $480.7M |
总债务CASHRARE
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
股东权益CASHRARE
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | $-80.0M | ||
| Q3 25 | $858.0M | $9.2M | ||
| Q2 25 | $819.0M | $151.3M | ||
| Q1 25 | $814.7M | $144.2M | ||
| Q4 24 | $758.3M | $255.0M | ||
| Q3 24 | $822.5M | $346.8M | ||
| Q2 24 | $748.4M | $432.4M |
总资产CASHRARE
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | $1.5B | ||
| Q3 25 | $7.2B | $1.2B | ||
| Q2 25 | $7.2B | $1.3B | ||
| Q1 25 | $7.0B | $1.3B | ||
| Q4 24 | $7.6B | $1.5B | ||
| Q3 24 | $7.5B | $1.5B | ||
| Q2 24 | $7.5B | $1.6B |
负债/权益比CASHRARE
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CASHRARE
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | $-99.8M | ||
| Q3 25 | $303.7M | $-91.4M | ||
| Q2 25 | $30.4M | $-108.3M | ||
| Q1 25 | $188.3M | $-166.5M | ||
| Q4 24 | $-71.7M | $-79.3M | ||
| Q3 24 | $143.1M | $-67.0M | ||
| Q2 24 | $113.2M | $-77.0M |
自由现金流CASHRARE
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $-100.8M | ||
| Q3 25 | $300.3M | $-92.7M | ||
| Q2 25 | $27.7M | $-110.7M | ||
| Q1 25 | $184.7M | $-167.8M | ||
| Q4 24 | $-73.8M | $-79.5M | ||
| Q3 24 | $138.8M | $-68.6M | ||
| Q2 24 | $111.0M | $-79.0M |
自由现金流率CASHRARE
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | -48.6% | ||
| Q3 25 | 160.9% | -58.0% | ||
| Q2 25 | 14.1% | -66.5% | ||
| Q1 25 | 67.2% | -120.5% | ||
| Q4 24 | -40.4% | -48.3% | ||
| Q3 24 | 77.3% | -49.2% | ||
| Q2 24 | 58.8% | -53.7% |
资本支出强度CASHRARE
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 0.5% | ||
| Q3 25 | 1.8% | 0.8% | ||
| Q2 25 | 1.4% | 1.5% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 1.1% | 0.1% | ||
| Q3 24 | 2.4% | 1.2% | ||
| Q2 24 | 1.2% | 1.4% |
现金转化率CASHRARE
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | — | ||
| Q3 24 | 4.27× | — | ||
| Q2 24 | 2.52× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
